posted
I belive this will be the stock of the year. Small float steady volum and climbing. Do your DD, at the end of November was .16 cents, now is .43 and climbing. Great product O24 pain killer, great management, the last comp. with the same CEO went from .90 cents to $42(yes forty two dollars). Chek them out you will be surprised.
Cheers!!
Max
Posts: 8 | From: NY | Registered: Jan 2005
| IP: Logged |
posted
Hi Max, Who is the CEO you are speaking of,the only former companys the current CEO Raghu Kilambi was a signatory with was JAWZ INC, and FUTURELINK CORP, both of which went through bankruptcy and now trade in the pinks. Not bashing here, I am a SWME fan and looking for the good stuff. Trade Well Max
-------------------- Bring me a shrubbery Posts: 69 | From: Maine | Registered: Jun 2004
| IP: Logged |
Here are some info regarding Mr. Kilampi. And by the way in the last few weeks any stock analyst talks about this company and potential. I've done it lot of research on it and I'm confident. But of course JMHO. I have lot of materials in regards of this, is all on the net.
Kilambi is a principal of Rubicon Investment Group; a Toronto-based merchant bank focused on private equity buyouts and active public market investments. Since 2001, Rubicon has made several successful investments in the information technology services and natural resources fields that have generated significant return on investments for Rubicon and its investors. Prior to Rubicon, Kilambi was Co-Founder and CFO of FutureLink Corp., an application service provider that had $140 million in revenue and a peak market capitalization of US$2 billion. FutureLink was a Forbes ASAP Top 25 Ramp Champ in 1999 and 2000. Kilambi led FutureLink's growth strategy, acquiring 8 companies and completing US$225 million of financing between 1998 and 2000. Previously, Kilambi was a merchant banker focused on funding growth companies, such as C2B Technologies (acquired by Inktomi/Yahoo). Kilambi earned a Bachelor of Commerce and a Graduate Diploma in Public Accounting from McGill University in Montreal and is a Chartered Accountant. "Raghu Kilambi was the perfect choice to lead Swiss Medica into the future," states Robert Kubbernus, the departing Chairman, CEO and CFO. "With our recently announced bioscience acquisitions, I knew that the company needed to be guided by an executive, such as Raghu, who understands how to rapidly grow new economy businesses on a global scale, while maintaining the strict financial controls necessary to meet corporate objectives and shareholder expectations. As our bioscience product suite has incredible potential for significant revenue growth, we needed an experienced executive team to realize this potential. As a large shareholder, I believe my investment in Swiss Medica is in very good hands with Kilambi at the helm," concludes Kubbernus. "I was pleased when Robert Kubbernus decided to singly focus Global Path on the high growth bioscience field and rename the company Swiss Medica. Swiss Medica's bioscience products are clearly one of the most attractive growth opportunities I have seen in my career," states Raghu Kilambi, new Chairman and CEO of Swiss Medica Inc. "I am very excited to lead Swiss Medica as we build a leading bioscience company. Our bioscience products have world-class endorsements and are in markets with revenue potentials greater than any of the new economy companies I have seen during my career. I look forward to the opportunity and challenge of building a strong team and commercializing these high potential products," concludes Kilambi.
Good trading!
Posts: 8 | From: NY | Registered: Jan 2005
| IP: Logged |
posted
TORONTO--(BUSINESS WIRE)--Dec. 30, 2004--Swiss Medica (OTCBB:SWME - News) is pleased to announce it has signed definitive agreements for debt financing, resulting in gross proceeds of US$1.5 million to fund the inventory and marketing requirements for the National U.S. launch of the Company's flagship O24(TM) pain relief product.
"This debt financing allows us to execute the launch phase of our ambitious marketing plan in the United States by using the same cost-efficient media strategy that has brought the O24 product a spectacular and devoted following in Canada," said Chief Executive Officer Raghu Kilambi. "Funds were raised from a group of institutional and high net worth investors with minimal equity dilution."
Full details of the financing will be incorporated in the Company's 8-K filing with the U.S. Securities and Exchange Commission.
By Michael Reynolds
On September 30th, Swiss Medica (OTC BB: SWME) was handed a godsend. Merck & Co announced a worldwide voluntary recall of its widely popular pain relief prescription medicine, Vioxx®. Swiss Medica scrambled to meet the avalanche of consumer demand for its all-natural O24™ topical pain reliever. Canada’s leading pharmacy chain quickly re-ordered after initial shipments were sold out. At the national AARP event in Las Vegas, seniors purchased up to several months supply of O24™ in case the product was not readily available to them in their neighborhood drugstore. “Recent congressional hearings and FDA statements about the safety concerns of arthritis, and other pain, pills gave Swiss Medica a strong sales surge early in this quarter,” said CEO Raghu Kilambi. “The more educated, health-conscious consumer wants a pain-relief product without the dangerous side effects so he or she can remain active and robust.” Sales of O24™ have increased exponentially quarter to quarter over the past year, and are could double in Q4 over the previous quarter.
TORONTO--(BUSINESS WIRE)--Dec 22, 2004 - Swiss Medica (OTCBB:SWME) is pleased to announce that the randomized double blind clinical trial using the O24(TM) pain relief product on patients suffering from fibromyalgia has been completed and a final report will be issued in January.
The clinical trials, which began October 1st, were recently concluded, according to Dr. Gordon Ko, medical director of the Canadian Centre for Integrative Medicine, who conducted the study. The results are currently being analyzed by the Institute of Clinical Evaluative Studies (ICES) in Toronto. There are 21,000 pages of data to be analyzed on the 150 fibromyalgia patients who were tested with the O24 product and a placebo over an extended period.
At present, there are no medications approved by the U.S. Food and Drug Administration (FDA) for treating fibromyalgia, a common and chronic disorder characterized by widespread muscle pain, fatigue, and multiple tender points.
ORONTO, ONTARIO, Dec 20, 2004 (CCNMatthews via COMTEX) -- Swiss Medica (OTCBB:SWME) has accelerated its efforts to reach physicians and healthcare professionals with the Company's O24(TM) pain relief product, following Friday's warning by the Food and Drug Administration that physicians consider alternatives to Pfizer's popular arthritis medication, and Cox-2 inhibitor, Celebrex(R); the Arthritis Foundation's recent caution in the use of any Cox-2 inhibitor; and a letter, to be published in the December 23rd issue of New England Journal of Medicine, by Vanderbilt University researchers, which warns clinicians against prescribing another Pfizer Cox-2 inhibitor, Bextra(R), "except in extraordinary circumstances."
"For the less severe cases of arthritis and other chronic pain ailments, I urge physicians, and other healthcare practitioners, to consider the non-synthetic nature of the O24(TM) pain relief product," said Allan N. Fields, D.O., who recently edited an information guide about the O24(TM) Essential Oil Pain Neutralizer, entitled Natural Relief for Musculoskeletal Pain. "I recommend O24(TM) as a topical delivery system, which may help reduce the frequent use of oral pain medications. Many patients can apply O24(TM) to their pain area for fast-acting and long-lasting pain relief without interfering with their current prescription medication. O24(TM) may be a safe solution for many who worry about the increased risk of heart attack from the Cox-2 inhibitor class, or the deleterious impact on the stomach lining from anti-inflammatory medicines such as aspirin, ibuprofen or naproxen, as reported in the media.
-------------------- Bring me a shrubbery Posts: 69 | From: Maine | Registered: Jun 2004
| IP: Logged |
Topic Closed
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
